Browse > Article
http://dx.doi.org/10.22643/JRMP.2022.8.1.39

Radioiodination strategies for carborane compounds  

Rajkumar Subramani (Department of Molecular Medicine, Brain Korea 21 four KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, School of Medicine, Kyungpook National University)
Abhinav Bhise (Department of Molecular Medicine, Brain Korea 21 four KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, School of Medicine, Kyungpook National University)
Jeongsoo Yoo (Department of Molecular Medicine, Brain Korea 21 four KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, School of Medicine, Kyungpook National University)
Publication Information
Journal of Radiopharmaceuticals and Molecular Probes / v.8, no.1, 2022 , pp. 39-44 More about this Journal
Abstract
The development of methods for the inert and stable radiohalogenation of targeted radiopharmaceuticals is a prerequisite for real-time diagnosis and therapy using radiohalogenated radiopharmaceuticals. Radiohalogenated carboranes demonstrate superior stability in vivo and versatile applications compared with directly labeled tyrosine analogues or synthetically modified organic compounds. Herein, we focus on the most common approaches for the radioiodination (123l, 124l, 125l, and 131l) of carborane derivatives.
Keywords
Radioiodination; Carborane; Boron Neutron Capture Therapy; Imaging;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Baker SJ, Ding CZ, Akama T, Zhang YK, Xia Y, Hernandez V. Therapeutic potential of boron containing compounds. Future Med Chem 2009;1:1275-8.   DOI
2 Baker SJ, Tomsho JW, Benkovic SJ. Boron-containing inhibitors of synthetases. Chem Soc Rev 2011;40:4279-5.
3 Das BC, Thapa P, Karki R, Schinke C, Das S, Kambhampati S, Banerjee SK, Veldhuizen van P, Verma A, Weiss LM, Evans T. Boron chemicals in diagnosis, therapeutics. Future Med Chem 2013;5:653-6.   DOI
4 Lesnikowski ZT. Challenges and opportunities for the application of boron clusters in drug design. J Med Chem 2016; 59:7738-8.   DOI
5 Kerr JA, in Handbook of chemistry and physics, 72nd ed.(Ed:D.R. Lide), CRC Press, Boca Raton, 1991;pp.9-3.
6 Wilbur DS, Chyan MK, Hamlin DK, Kegley BB, Risler R, Pathare PM, Quinn J, Vessella RL Foulton C, Zalutsky M, Wedge TJ, Hawthorne MF. Reagents for Astatination of biomolecules: Comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. Bioconjugate Chem2004;15:203-3.   DOI
7 Ghirmai S, Malmquist J, Lundquist H, Tolmachev V, Sjoberg S. Synthesis and radioiodination of 7-(30-ammoniopropyl)-7,8-dicarba-nido-undecaborate(-1), (ANC). J Lahelled Compd Radwpharm. 2004;47: 557-9.   DOI
8 Guerard F, X Gestin JF, and Brechbiel MW. Production of [211At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy. Cancer Biother Radiopharm 2013;28(1):1-20.
9 Varadarajan A, Sharkey RM, Goldenberg DM, Hawthorne MF. Conjugation of phenyl isothiocyanate derivatives of carborane to antitumor antibody and in vivo localization of conjugates in nude mice. Bioconjugate Chem 1991;2:102-10.   DOI
10 Bregadze VI, Sivaev IB, Glazun SA Polyhedral boron compounds as potential diagnostic and therapeutic antitumor agents. Anti-Can-cer Agents in Medicinal Chemistry 2006; 6: 75-9.   DOI
11 Grimes RN. Carboranes. Academic Press, New Yark 1970.
12 Winberg KJ, Barbera G, Eriksson L, Teixidor F, Tolmachev V, vrnas C, Sjoberg S. J Organomet Chem 2003;680:188-2.
13 Tolmachev V, Koziorowski J, Sivaev I, Lundqvist H, Carlsson J, Orlova A, Gedda L, Olsson P, Sjoberg S, Sundin A. Bioconjugate Chem 1999;10:338-5.
14 El-Zaria ME, Janzen N, Blacker M, Valliant JF. Synthesis, characterisation, and biodistribution of radioiodinated C-hydroxy-carboranes. Chem Eur 12012;18:11071-8.